HanchorBio
Business Services · Taiwan · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1號 Neihu District Section 1 Tiding Blvd ...Phone Number
+886 227921366Website
www.hanchorbio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About HanchorBio
HanchorBio is a global clinical-stage biotechnology company focused on pioneering transformative immunotherapies for oncology and autoimmune diseases. The company is dedicated to innovating for life and inspiring hope through its advanced research and development projects, which include over 100 patent applications and a significant investment in R&D. HanchorBio's core technology platform combines innate and adaptive immune systems to effectively target tumor cells. Their intended clients include healthcare professionals and organizations involved in cancer treatment and research.Explore more
HanchorBio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is HanchorBio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on HanchorBio recently announced quarterly report
Click to see if HanchorBio had a recent Job posting/layoffs
HanchorBio, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when HanchorBio launches new products
Funding: Get notified immidiatlly once HanchorBio has new funding data
Congratulate Masked Content for being promoted to Masked Content at HanchorBio
Check out if HanchorBio is spiking on competitors!
Check if HanchorBio has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at HanchorBio
Find 3 more new buyers
Company Profile Activity
Activity Insights
HanchorBio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
HanchorBio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about HanchorBio.
HanchorBio Tech Stack
A closer look at the technologies used by HanchorBio
HanchorBio News & Media
HanchorBio Tests Broader Ambitions for HCB101 Through InxMed Partnership
Taiwan-listed biotech looks to expand the value of its lead oncology asset through combination research with late-stage cancer drug resistance specialist InxMed. TAIPEI and SHANGHAI and SAN FRANCISCO, July 9, 2026 /PRNewswire/ -- HanchorBio, Inc. (TWSE: 7827) is taking another step to broaden the development path for HCB101, its lead oncology asset, through a new partnership with InxMed. The Taiwan-listed clinical-stage biotech announced that its subsidiary, FBD Biologics Limited, has signed a sHanchorBio Tests Broader Ambitions for HCB101 Through InxMed Partnership
Taiwan-listed biotech looks to expand the value of its lead oncology asset through combination research with late-stage cancer drug resistance specialist InxMed. TAIPEI and SHANGHAI and SAN FRANCISCO, July 8, 2026 /PRNewswire/ -- HanchorBio, Inc. (TWSE: 7827) is taking another step to...HanchorBio to List on Taiwan Innovation Board at NT$120 per Share as HCB101 Clinical Data Support Global Partnering Discussions
Global clinical-stage biotech x FBDB™ platform and multi-indication development strategy for lead program HCB101 TAIPEI, SHANGHAI, SAN FRANCISCO, May 28, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation...HanchorBio Prices IPO at NT$120 Ahead of Innovation Board Listing on May 29
TAIPEI and SHANGHAI and SAN FRANCISCO, May 26, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced the completion of bookbuilding for its initial public offering on the Taiwan Innovation Board. The offering price has been set at NT$120 per share. HanchorBio is expected to list on the Taiwan Innovation Board on May 29, 2026. The offering attracted strong in
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding HanchorBio
Sign Up For FreeTo access detailed company insights
HanchorBio is a global clinical-stage biotechnology company focused on pioneering transformative immunotherapies for oncology and autoimmune diseases. The company is dedicated to innovating for life and inspiring hope through its advanced research and development projects, which include over 100 patent applications and a significant investment in R... Read More
